Codexis (CDXS) Earning Somewhat Positive News Coverage, Report Shows

Headlines about Codexis (NASDAQ:CDXS) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Codexis earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.4856466280785 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

Several research firms recently issued reports on CDXS. HC Wainwright set a $8.00 price target on Codexis and gave the company a “buy” rating in a research report on Friday. BidaskClub lowered Codexis from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Zacks Investment Research raised Codexis from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, July 19th. ValuEngine lowered Codexis from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Finally, Jefferies Group LLC started coverage on Codexis in a research report on Wednesday, May 31st. They issued a “buy” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Codexis has an average rating of “Hold” and a consensus target price of $6.80.

Codexis (NASDAQ CDXS) traded down 1.87% on Friday, hitting $5.25. The stock had a trading volume of 198,309 shares. The firm’s 50-day moving average price is $5.35 and its 200-day moving average price is $4.72. Codexis has a 1-year low of $3.60 and a 1-year high of $5.70. The firm’s market cap is $216.59 million.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $10.30 million during the quarter, compared to the consensus estimate of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. The company’s quarterly revenue was down 35.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.12 EPS. On average, equities research analysts predict that Codexis will post ($0.32) earnings per share for the current year.

WARNING: “Codexis (CDXS) Earning Somewhat Positive News Coverage, Report Shows” was originally reported by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/codexis-cdxs-receives-news-sentiment-score-of-0-18-updated.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply